Next, for the five genes targeted by inhibitors, VCAM1, F11, KLKB1, GP1BA and LAMC2, we examined the associations of rare deleterious variants (MAF < 0.01) with stroke and stroke-related traits, applying gene-based burden tests to whole-exome sequencing data from >450,000 UK Biobank participants to support potential therapeutic targets for inhibitors31. Here, VCAM1 is linked to stroke disorder.